FKBPL: A NOVEL TARGET FOR  OBESITY AND METABOLIC  SYNDROME front page preview

FKBPL: A NOVEL TARGET FOR OBESITY AND METABOLIC SYNDROME

RCSI researchers have discovered a novel target, FKBPL, which regulates energy expenditure, and have shown that obesity and Type 2 diabetes (T2D) develop when levels of this protein are low in mice and humans. Proof of...

pdf 272.8KB

STARMAT – A Versatile Star  Polypeptide Platform for  Oligonucleotide Drug Delivery front page preview

STARMAT – A Versatile Star Polypeptide Platform for Oligonucleotide Drug Delivery

Star-polymers are a new class of polymer architecture which consist of linear arms radiating from a central core. Novel Star polypeptide-based vectors discovered at RCSI have superior transfection and delivery efficacy...

pdf 436.5KB

Modulating macrophage plasticity for the treatment of disease front page preview

Modulating macrophage plasticity for the treatment of disease

Researchers in RCSI have discovered that enhancing the expression of a particular enzyme maintains macrophages in an anti-inflammatory and tissue regenerative state. They have developed a target site blocker which up-reg...

pdf 305.4KB

Highly Selective Inhibitors of HDAC6 for the Treatment of Cancers and Neurodegenerative Disease front page preview

Highly Selective Inhibitors of HDAC6 for the Treatment of Cancers and Neurodegenerative Disease

A novel structural class of highly-selective HDAC6 inhibitors. These patented small molecules have a unique non-hydroxamic acid chemical structure. The lead compound BAS-2 has been shown to inhibit glycolysis in triple ...

pdf 463.4KB

Modifying Macrophages for the Treatment of Inflammatory Diseases front page preview

Modifying Macrophages for the Treatment of Inflammatory Diseases

Macrophages are a sub-type of immune cells that are critical for fighting infection in the body through the release of inflammatory and toxic mediators. However if inflammation persists these Macrophages become destructi...

pdf 306.3KB